Omidon Tablet 10mg

Omidon

Domperidone tablet/dispersible

tablet/suspension/paediatric drops

Presentation Omidon Tablet: Each film coated tablet contains Domperidone Maleate BP equivalent to 10 mg

Domperidone.

Omidon D Tablet: Each dispersible tablet contains Domperidone BP 10 m Omidon Suspension: Each 5 ml suspension contains Domperidone BP 5 mg Omnidon Paediatric dropa: Each mil paediatric drops contains Domperidone BP 5 mg Omidon is a Dopamine antagonist. Because it does not readily enter the central nervous system, its effects are confined to the periphery and acts principally at the receptor in the chemoreceptor

Description

trigger zone.

Indications

1. Stimulation of gut mobility

a) Non-ulcer dyspepsia

b) Esophageal reflux, reflux esophagitis and gastritis

c) Diabetic gastroparesis

d) Functional dyspepsia

e) Speeding barium transit in follow-through radiological studies

2. Prevention and symptomatic reliet of acute nausea and vomiting from any cause

including cytotoxic therapy, radio therapy and anti-parkinsonism therapy. 3. In the treatment of migraine.

Dosage and Administration The recommended oral dose for

Adults: 10-20 mg every 4-8 hours daily

Children: 0.2-0.4 mg/kg every 4-8 hours daily.

Note: Omidon tablet and suspension should be taken 15-30 minutes before meal. For acute nausea and vomiting, maximum period of treatment is 12 weeks

Contraindications

Domperidone is contraindicated to patients who have known hypersensitivity to this drug case of neonates.

Precautions

Domperidone should be used with absolute caution in case of children because there may be an increased risk of extra-pyramidal rodotions in young children because of an incompletely developed blood-brain barrier

Side-effects

Domperidone may produce hyperprolactinemia (1.3% frequency). This may result in galactitica breast enlargement and soreness and reduced libido. Dry mouth (19%), thirst, headache (12%). nervousness, drowsiness (0.4%), diarrhea (0.2%), skin rash and itching (0.1%) may occur during treatment with Domperidome. Extra-pyramidal reactions are seen in 0.05% of patients in clinical

studies

Use In Pregnancy & Lactation

Pregnant women: The safety of Domperidone has not been proven and it is therefore not recommended during pregnancy Animal studies have not demonstrated teratogenic effects on the Lactating mother: Domperidone may precipitate galactorrhea and improve post-natal lactation. It is secreted in breast milk but in very small quantities, insufficient to be considered harmful.

fetus.

Drug Interactions

Domperidone may reduce the hypoprolactinemic effect of bromocriptine. The action Domperidone on Gl function may be antagonized by anti-muscarinics and opioid analgesics

Overdosage

There are no reported cases of overdosage.

Storage

Do not store above 30 °C. Keep away from light and out of the reach of children.

Commercial Pack Omidan Tablet: Each box contains 10 blister strips of 10 tablets.

Omidon D Tablet: Each box contains 10 blister strips of 10 tablets. Omidon Suspension: Each bottle contains 60 ml of suspension.

Omidon Paediatric drops: Each bottle contains 15 ml of paediatric suspension.

Incepta

Manufactured by

Incepta Pharmaceuticals Ltd

Savar, Dhaka, Bangladesh Registered Trademark.